Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 94.9% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 522,716 shares, a growth of 94.9% from the July 15th total of 268,144 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,354,099 shares, the days-to-cover ratio is presently 0.4 days.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY remained flat at $13.84 during midday trading on Friday. 396,144 shares of the company’s stock traded hands, compared to its average volume of 990,166. The stock has a market cap of $54.39 billion, a PE ratio of -27.14, a price-to-earnings-growth ratio of 4.34 and a beta of 0.55. The firm has a 50 day simple moving average of $13.03 and a 200 day simple moving average of $12.18. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. Bayer Aktiengesellschaft has a twelve month low of $7.48 and a twelve month high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion for the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts predict that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BAYRY. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.